Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Table 4

Report on all papers about cabozantinib and stomatitis.

	Authors	Year	Neoplasia	nNumber of cases	Stomatitis total	Stomatitis grade 1	Stomatitis grade 2	Stomatitis grade 3	Stomatitis grade 4
1	Neal et al. [61]	2016	Phase II trial for EGFR wild-type non-small-cell lung cancer; A: erlotinib; B: cabozantinib; C: erlotinib + cabozantinib	A: 40; B: 40; C: 39	A: 2 (5%); B: 17 (43%); C: 9 (24%)	A: 2 (5%); B: 13 (33%); C: 8 (21%)		A: 0; B: 4 (10%); C: 1 (3%)	A: 0; B: 0; C: 0
2	Tolaney et al. [62]	2017	Phase II metastatic triple negative breast cancer; A: oral dosing of cabozantinib at 60 mg daily over a 21-day cycle	A: 35	A: 13 (37%)	A: 11	A: 2	A: 0	A: 0
	Total			114	39 (34.21%)	34 (29.82%)		5 (4.38%)